Prelude Therapeutics

Prelude Shifts Focus, Cuts Phase 1 Drugs in New Deal

Prelude Focuses on SMARCA in AbCellera Deal and Trims Its Portfolio by Dropping Two Phase 1 Candidates

Anika Sharma

Prelude Therapeutics is undergoing a strategic shift, significantly streamlining its clinical pipeline to focus on the promising potential of its ...